VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has reported new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The new data demonstrated that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and exhibited dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, these results suggest a potential for reducing off-target effects common with traditional antibody-drug conjugates.
VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026. The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates, T-cell engagers, and other antibody-based formats.
VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. The company’s progress with its BiTAC platform marks a step forward in the development of next-generation cancer therapies that could offer improved efficacy and safety profiles.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company’s filings with the SEC. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. For full terms of use and disclaimers, visit http://IBN.fm/Disclaimer.
